Biblio
Export 1160 results:
Author Title [ Type![(Desc)](https://www.j-alz.com/sites/all/modules/contrib/biblio/misc/arrow-desc.png)
Filters: First Letter Of Last Name is R [Clear All Filters]
“Protective Effects of Indian Spice Curcumin Against Amyloid-β in Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 3, pp. 843-866, 2018.
, “Protective Effects of Indian Spice Curcumin Against Amyloid-β in Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 3, pp. 843-866, 2018.
, “Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 49, no. 4, pp. 927-43, 2016.
, “Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 49, no. 4, pp. 927-43, 2016.
, “Proteome Profiling Identified Amyloid-β Protein Precursor as a Novel Binding Partner and Modulator of VGLUT1.”, J Alzheimers Dis, vol. 81, no. 3, pp. 981-1038, 2021.
, “Proteomic Profiles of Neurodegeneration Among Mexican Americans and Non-Hispanic Whites in the HABS-HD Study.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1243-1254, 2022.
, “Protofibrillar and Fibrillar Amyloid-β Binding Proteins in Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 66, no. 3, pp. 1053-1064, 2018.
, “Psychometric Properties of Apathy Scales in Dementia: A Systematic Review.”, J Alzheimers Dis, vol. 66, no. 3, pp. 1065-1082, 2018.
, “Psychometric Properties of Apathy Scales in Dementia: A Systematic Review.”, J Alzheimers Dis, vol. 66, no. 3, pp. 1065-1082, 2018.
, “Psychometric Properties of Apathy Scales in Dementia: A Systematic Review.”, J Alzheimers Dis, vol. 66, no. 3, pp. 1065-1082, 2018.
, “Psychopharmacological Medication Use in Frontotemporal Dementia at the Time of Diagnosis: Comparison with Alzheimer's Disease.”, J Alzheimers Dis, vol. 95, no. 2, pp. 677-685, 2023.
, “Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions.”, J Alzheimers Dis, vol. 88, no. 4, pp. 1203-1228, 2022.
, “Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions.”, J Alzheimers Dis, vol. 88, no. 4, pp. 1203-1228, 2022.
, “Psychosocial Risk and Protective Factors and Incident Mild Cognitive Impairment and Dementia in Community Dwelling Elderly: Findings from the Singapore Longitudinal Ageing Study.”, J Alzheimers Dis, vol. 57, no. 2, pp. 603-611, 2017.
, “Psychotropic Drug Prescription in Patients with Dementia: Nursing Home Residents Versus Patients Living at Home.”, J Alzheimers Dis, vol. 49, no. 3, pp. 671-80, 2016.
, “Psychotropic Drug Prescription in Patients with Dementia: Nursing Home Residents Versus Patients Living at Home.”, J Alzheimers Dis, vol. 49, no. 3, pp. 671-80, 2016.
, “Purported Interactions of Amyloid-β and Glucocorticoids in Cytotoxicity and Genotoxicity: Implications in Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 3, pp. 1085-1094, 2016.
, “Putative Dementia Cases Fluctuate as a Function of Mini-Mental State Examination Cut-Off Points.”, J Alzheimers Dis, vol. 61, no. 1, pp. 157-167, 2018.
, “Putative Gonadotropin-Releasing Hormone Agonist Therapy and Dementia: An Application of Medicare Hospitalization Claims Data.”, J Alzheimers Dis, vol. 63, no. 4, pp. 1269-1277, 2018.
, “A Qualitative Impairment in Face Perception in Alzheimer's Disease: Evidence from a Reduced Face Inversion Effect.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1225-36, 2016.
, “A Qualitative Impairment in Face Perception in Alzheimer's Disease: Evidence from a Reduced Face Inversion Effect.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1225-36, 2016.
, “Quality of Life, Care Resource Use, and Costs of Dementia in 8 European Countries in a Cross-Sectional Cohort of the Actifcare Study.”, J Alzheimers Dis, vol. 66, no. 3, pp. 1027-1040, 2018.
, “Quality of Life in Advanced Dementia with Late Onset, Young Onset, and Very Young Onset.”, J Alzheimers Dis, vol. 80, no. 1, pp. 283-297, 2021.
, “Quality of Life in Advanced Dementia with Late Onset, Young Onset, and Very Young Onset.”, J Alzheimers Dis, vol. 80, no. 1, pp. 283-297, 2021.
, “Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer's Disease.”, J Alzheimers Dis, vol. 58, no. 2, pp. 491-505, 2017.
,